BACK

John D. Bradley

John D. Bradley

Managing Director

New York Office  |  john.bradley@torreya.com   |   212.257.5805

John Bradley, a Managing Director at Torreya, works with the firm’s financing and M&A businesses. John has a vast network of relationships in the life sciences industry, as well as with family offices and high net worth individuals worldwide. An expert in branded pharmaceuticals and drug delivery, he has raised over $500 million in public and private capital for many pharmaceutical, insurance, and technology companies.

John has more than 40 years of corporate finance experience as an executive within both pharmaceutical companies and investment banks. He has also managed the assets of several large family offices.

His career highlights prior to joining Torreya in 2008 include Co-Founder and Chairman of the Board of Mystic Pharmaceuticals; Founder and Chairman of VentureLink; early-stage financings of many pharmaceutical companies, including Watson Pharmaceuticals (now part of Allergan Pharma), Ethical Holdings, Ltd., Caraco Pharmaceuticals (now part of Sun Pharma), and Lemmon Pharmacal, Inc. (now part of Teva Pharmaceuticals, Inc.); and President and Founder of Bradley-Hummel & Co., Inc., a NYSE member firm. Earlier in his career, he held positions at Brown Brothers Harriman and Drexel Burnham Lambert & Co.

John is a senior advisor to the New York Center for Living – Rehabilitation Center for Adolescents and Young Adults.

He is a registered representative with Financial West Group.

Selected Transactions

Crown Laboratories
Sale of
majority equity stake to
Hildred
Undisclosed
December 2017
Rubicon Research
Sale of equity stake to
Everstone Group
$33 million
November 2016
Amerigen
Senior term loan
Undisclosed
$15 million
December 2015
Canterbury Laboratories
Merger into
Restorgenex
Undisclosed
September 2013
Molecular Insight
Sale for up to
$106 million to
Progenics
$12 million +
milestones
January 2013
Cambrooke Therapeutics
Preferred equity investment
undisclosed
$7 million
January 2016